Cargando…

External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients

BACKGROUND: A prognostic model based on the results of molecular analysis of sentinel lymph nodes (SLN) is needed to replace the information that staging the entire axilla provided. The aim of the study is to conduct an external validation of a previously developed model for the prediction of 5-year...

Descripción completa

Detalles Bibliográficos
Autores principales: Piñero-Madrona, Antonio, Ripoll-Orts, Francisco, Sánchez-Méndez, José Ignacio, Chaves-Benito, Asunción, Gómez-de la Bárcena, Maximiliano Rodrigo, Calatrava-Fons, Ana, Menjón-Beltrán, Salomón, Peg-Cámara, Vicente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188708/
https://www.ncbi.nlm.nih.gov/pubmed/32253684
http://dx.doi.org/10.1007/s10549-020-05623-4
_version_ 1783527350054420480
author Piñero-Madrona, Antonio
Ripoll-Orts, Francisco
Sánchez-Méndez, José Ignacio
Chaves-Benito, Asunción
Gómez-de la Bárcena, Maximiliano Rodrigo
Calatrava-Fons, Ana
Menjón-Beltrán, Salomón
Peg-Cámara, Vicente
author_facet Piñero-Madrona, Antonio
Ripoll-Orts, Francisco
Sánchez-Méndez, José Ignacio
Chaves-Benito, Asunción
Gómez-de la Bárcena, Maximiliano Rodrigo
Calatrava-Fons, Ana
Menjón-Beltrán, Salomón
Peg-Cámara, Vicente
author_sort Piñero-Madrona, Antonio
collection PubMed
description BACKGROUND: A prognostic model based on the results of molecular analysis of sentinel lymph nodes (SLN) is needed to replace the information that staging the entire axilla provided. The aim of the study is to conduct an external validation of a previously developed model for the prediction of 5-year DFS in a group of breast cancer patients that had undergone SLN biopsy assessed by the One Step Nucleic Acid Amplification (OSNA) method. METHODS: We collected retrospective data of 889 patients with breast cancer, who had not received systemic treatment before surgery, and who underwent SLN biopsy and evaluation of all SLN by OSNA. The discrimination ability of the model was assessed by the area under the ROC curve (AUC ROC), and its calibration by comparing 5-years DFS Kaplan–Meier estimates in quartile groups of model predicted probabilities (MPP). RESULTS: The AUC ROC ranged from 0.78 (at 2 years) to 0.73 (at 5 years) in the training set, and from 0.78 to 0.71, respectively, in the validation set. The MPP allowed to distinguish four groups of patients with heterogeneous DFS (log-rank test p < 0.0001). In the highest risk group, the HR were 6.04 [95% CI 2.70, 13.48] in the training set and 4.79 [2.310, 9.93] in the validation set. CONCLUSIONS: The model for the prediction of 5-year DFS was successfully validated using the most stringent form of validation, in centers different from those involved in the development of the model. The external validation of the model confirms its utility for the prediction of 5-year DFS and the usefulness of the TTL value as a prognostic variable. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-020-05623-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7188708
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-71887082020-05-04 External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients Piñero-Madrona, Antonio Ripoll-Orts, Francisco Sánchez-Méndez, José Ignacio Chaves-Benito, Asunción Gómez-de la Bárcena, Maximiliano Rodrigo Calatrava-Fons, Ana Menjón-Beltrán, Salomón Peg-Cámara, Vicente Breast Cancer Res Treat Clinical Trial BACKGROUND: A prognostic model based on the results of molecular analysis of sentinel lymph nodes (SLN) is needed to replace the information that staging the entire axilla provided. The aim of the study is to conduct an external validation of a previously developed model for the prediction of 5-year DFS in a group of breast cancer patients that had undergone SLN biopsy assessed by the One Step Nucleic Acid Amplification (OSNA) method. METHODS: We collected retrospective data of 889 patients with breast cancer, who had not received systemic treatment before surgery, and who underwent SLN biopsy and evaluation of all SLN by OSNA. The discrimination ability of the model was assessed by the area under the ROC curve (AUC ROC), and its calibration by comparing 5-years DFS Kaplan–Meier estimates in quartile groups of model predicted probabilities (MPP). RESULTS: The AUC ROC ranged from 0.78 (at 2 years) to 0.73 (at 5 years) in the training set, and from 0.78 to 0.71, respectively, in the validation set. The MPP allowed to distinguish four groups of patients with heterogeneous DFS (log-rank test p < 0.0001). In the highest risk group, the HR were 6.04 [95% CI 2.70, 13.48] in the training set and 4.79 [2.310, 9.93] in the validation set. CONCLUSIONS: The model for the prediction of 5-year DFS was successfully validated using the most stringent form of validation, in centers different from those involved in the development of the model. The external validation of the model confirms its utility for the prediction of 5-year DFS and the usefulness of the TTL value as a prognostic variable. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-020-05623-4) contains supplementary material, which is available to authorized users. Springer US 2020-04-06 2020 /pmc/articles/PMC7188708/ /pubmed/32253684 http://dx.doi.org/10.1007/s10549-020-05623-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Trial
Piñero-Madrona, Antonio
Ripoll-Orts, Francisco
Sánchez-Méndez, José Ignacio
Chaves-Benito, Asunción
Gómez-de la Bárcena, Maximiliano Rodrigo
Calatrava-Fons, Ana
Menjón-Beltrán, Salomón
Peg-Cámara, Vicente
External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients
title External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients
title_full External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients
title_fullStr External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients
title_full_unstemmed External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients
title_short External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients
title_sort external validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188708/
https://www.ncbi.nlm.nih.gov/pubmed/32253684
http://dx.doi.org/10.1007/s10549-020-05623-4
work_keys_str_mv AT pineromadronaantonio externalvalidationofaprognosticmodelbasedontotaltumorloadofsentinellymphnodeforearlybreastcancerpatients
AT ripollortsfrancisco externalvalidationofaprognosticmodelbasedontotaltumorloadofsentinellymphnodeforearlybreastcancerpatients
AT sanchezmendezjoseignacio externalvalidationofaprognosticmodelbasedontotaltumorloadofsentinellymphnodeforearlybreastcancerpatients
AT chavesbenitoasuncion externalvalidationofaprognosticmodelbasedontotaltumorloadofsentinellymphnodeforearlybreastcancerpatients
AT gomezdelabarcenamaximilianorodrigo externalvalidationofaprognosticmodelbasedontotaltumorloadofsentinellymphnodeforearlybreastcancerpatients
AT calatravafonsana externalvalidationofaprognosticmodelbasedontotaltumorloadofsentinellymphnodeforearlybreastcancerpatients
AT menjonbeltransalomon externalvalidationofaprognosticmodelbasedontotaltumorloadofsentinellymphnodeforearlybreastcancerpatients
AT pegcamaravicente externalvalidationofaprognosticmodelbasedontotaltumorloadofsentinellymphnodeforearlybreastcancerpatients